Antiemetic care for patients with breast cancer: Focus on drug interactions and safety concerns

American Journal of Health-System Pharmacy

Volumn 64, Issue 21, 2007, Pages 2227-2236

  Georgy, Angela ^a   Neceskas, Jacalyn ^b   Goodin, Susan ^b,c  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Antiemetics; Antineoplastic agents; Breast neoplasms; Combined therapy; Drug interactions; Drugs; Mechanism of action; Nausea; Steroids, cortico ; Toxicity

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DOPAMINE RECEPTOR BLOCKING AGENT; SEROTONIN ANTAGONIST; TACHYKININ RECEPTOR ANTAGONIST;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; DRUG SAFETY; HUMAN; NAUSEA; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

EID: 36048948959     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060609     Document Type: Review

References (87)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology, 2004. www.nccn.org/professionals/physician_gls/ (accessed 2006 Oct 29).
3. Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 2005; 12:721-47.
4. National Cancer Institute. Search results for clinical trials of breast cancer. www.cancer.gov/search/ResultsClinicalTrials.aspx?protocolsearchid= 3494734 (accessed 2007 Jul 31).
5. Griffin AM, Butow PN, Coates AS et al. On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7:189-95.
6. Sun CC, Bodurka DC, Weaver CB et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005; 13:219-27.
7. Lindley C, McCune JS, Thomason TE et al. Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract. 1999; 7:59-65.
8. American Cancer Society. Estimated new cancer cases by sex and age, 2007. www.cancer.org/downloads/PRO/2007_cases_8__deaths_by_age.pdf (accessed 2007 Aug 20).
9. Doherty KM. Closing the gap in prophylactic antiemetic therapy: patient factors in calculating the emetogenic potential of chemotherapy. Clin J Oncol Nurs. 1999; 3:113-9.
10. Haug TT, Mykletun A, Dahl AA. The prevalence of nausea in the community: psychological, social and somatic factors. Gen Hosp Psychiatry. 2002; 24:81-6.
11. Pare P, Ferrazzi S, Thompson WG et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001; 96:3130-7.
12. Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control. 2000; 7:548-56.
13. Jorgensen T, Johansson S, Kennerfalk A et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001; 35:1004-9.
14. Karas S Jr. The potential for drug interactions. Ann Emerg Med. 1981; 10:627-30.
15. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer. 2005; 13:80-4.
16. Feyer PC, Maranzano E, Molassiotis A et al. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer. 2005; 13:122-8.
17. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24:2932-47. [Erratum, J Clin Oncol. 2006; 24:5341-2.]
18. Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. www.mascc.org/content/127.html (accessed 2007 Aug 1).
19. Tonato M, Clark-Snow RA, Osoba D et al. Emesis induced by low or minimal emetic risk chemotherapy. Support Care Cancer. 2005; 13:109-11.
20. Kris MG, Hesketh PJ, Herrstedt J et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005; 13:85-96.
21. Herrstedt J, Koeller JM, Roila F et al. Acute emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005; 13:97-103.
22. Roila F, Warr D, Clark-Snow RA et al. Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer. 2005; 13:104-8.
23. Fiets WE, van Helvoirt RP, Nortier JW et al. Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients: a prospective, comparative, non-randomised study. Eur J Cancer. 2003; 39:1081-8.
24. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-9.
25. Bilgrami S, Fallon B. Chemotherapy-induced nausea and vomiting: easing patients' fear and discomfort with effective antiemetic regimens. Postgrad Med. 1993; 94:55-64.
26. Danjoux CE, Rider WD, Fitzpatrick PJ. The acute radiation syndrome. A memorial to William Michael Court-Brown. Clin Radiol. 1979; 30:581-4.
27. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm. 1999; 56:729-64.
28. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999; 17:2971-94. [Errata, J Clin Oncol. 1999; 17:3860; J Clin Oncol. 2000; 18:3064.]
29. Koeller JM, Aapro MS, Gralla RJ et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer. 2002; 10:519-22.
30. Blower P. 5-HT3 receptor antagonists-receptor interaction and implications for duration of antiemetic effect. Support Care Cancer. 2005; 13:413. Abstract.
31. Zofran (ondansetron hydrochloride) prescribing information. Research Triangle Park, NC: Glaxo Wellcome; 2000.
32. Anzemet (dolasetron mesylate) prescribing information. Kansas City, MO: Avenus Pharmaceuticals; 2003.
33. Navoban (tropisetron) prescribing information. North Ryde, Australia: Novartis Pharmaceuticals Australia; 1997.
34. Kytril (granisetron hydrochloride) prescribing information. Nutley, NJ: Roche Laboratories; 2000.
35. Piraccini G, Gallagher S, Macchiocchi A. Palonosetron: a phase II dose ranging study to assess, over a 7-day period, the single-dose pharmacokinetic profile of palonosetron in patients receiving highly emetogenic chemotherapy. Proc Am Soc Clin Oncol. 2002; 21:449. Abstract.
36. Aloxi (palonosetron HCl) injection prescribing information. Bloomington, MN: MGI Pharma; 2003.
37. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14:1570-7.
38. 3 receptor antagonist. Results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98:2473-82.
39. Upward JW, Arnold BD, Link C et al. The clinical pharmacology of granisetron (BRL 43694), a novel specific 5-HT3 antagonist. Eur J Cancer. 1990; 26(suppl 1):S12-5.
40. Emend (aprepitant) prescribing information. Whitehouse Station, NJ: Merck; 2005.
41. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23:2822-30.
42. Blower P, De Wit R, Goodin S et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005; 55:117-42.
43. Corcoran M. Polypharmacy in the older patient with cancer. Cancer Control. 1997; 4:419-28.
44. Vestal R. Aging and pharmacology. Cancer. 1997; 80:1302-10.
45. Anantharaju A, Feller A, Chedid A. Aging liver. A review. Gerontology. 2002; 48:343-53.
46. Davis M, Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer. 2001; 9:442-51.
47. Kaiser R, Sezer O, Papies A et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002; 20:2805-11.
48. De Bruijn K. Tropisetron: a review of the clinical experience. Drugs. 1992; 43:11-22.
49. 3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J. 2002; 8:405-14.
50. Cagnoni PJ, Matthes S, Day TC et al. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. Bone Marrow Transplant. 1999;24:1-4.
51. Koriech O. Fluoxetine treatment compromises the antiemetic efficacy of ondansetron in cancer patients. Clin Oncol. 1995; 7:371-2.
52. 3 spinal receptor involvement in acute pain in humans. Anesth Analg. 2002; 94:1553-7.
53. Eisenberg P, MacKintosh FR, Ritch P et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol. 2004; 15:330-7.
54. Food and Drug Administration. Aprepitant FDA Advisory Committee background package. March 6, 2003. www.fda.gov/ohrms/dockets/ac/03/briefing/ 3928bl.htm (accessed 2006 Mar 15).
55. De Jonge ME, Huitema AD, Holtkamp MJ et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005; 56:370-8.
56. Blum RA, Majumdar A, McCrea J et al. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003; 25:1407-19.
57. Shah AK, Hunt TL, Gallagher SC et al. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin. 2005; 21:595-601.
58. Algra A, Tijssen JG, Roelandt JR et al. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation. 1991; 83:1888-94.
59. Cubbedu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther. 2003; 10:452-7.
60. Adams MJ, Hardenbergh PH, Constine LS et al. Radiation-associated cardiovascular disease. Cut Rev Oncol Hematol. 2003; 45:55-75.
61. Arsenian MA. Cardiovascular sequelae of therapeutic thoracic radiation. Prog Cardiovasc Dis. 1991; 33:299-312.
62. Rutqvist LE, Lax I, Fornander T et al. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys. 1992; 22:887-96.
63. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002; 4:235-42.
64. Keefe DL, Roistacher N, Pierri MK. Clinical cardiotoxicity of 5-fluorouracil. J Clin Pharmacol. 1993; 33:1060-70.
65. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344:783-92.
66. Piccart-Gebhart M. First results of the HERA trial. A randomized three-arm multi-centre comparison of 1 year herceptin, 2 years herceptin or no herceptin in women with HER-2 positive primary breast cancer who have completed adjuvant chemotherapy. Paper presented at ASCO Annual Meeting. Orlando, FL; 2005 May 16.
67. Romond E. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer. Combined analysis of NSABP-B31-NCCTG-N9831. Paper presented at ASCO Annual Meeting. Orlando, FL; 2005 May 16.
68. Keefe D. Cardiovascular emergencies in the cancer patient. Semin Oncol. 2000; 27:244-55.
69. Ryberg M, Nielsen D, Skovsgaard T et al. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J Clin Oncol. 1998; 16:3502-8.
70. Wei JY. Cardiovascular comorbidity in the older cancer patient. Semin Oncol. 1995; 22:9-10.
71. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med. 2006;57:485-98.
72. Pinder MC, Duan Z, Goodwin JS et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. In press.
73. Venturini M, Lunardi G, Del Mastro L et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol. 2000; 18:2116-25.
74. Grasselli G, Vigano L, Capri G et al. Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. J Clin Oncol. 2001; 19:2222-31.
75. Minotti G, Saponiero A, Licata S et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res. 2001; 7:1511-5.
76. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects. Semin Oncol. 2001; 28:15-23.
77. Gianni L, Dombernowsky P, Sledge G et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol. 2001; 12:1067-73.
78. Bates SE, Rosing DR, Fojo R et al. Challenges of evaluating the cardiac effects of anticancer agents. Clin Cancer Res. 2006; 12:3871-3.
79. Benedict CR, Arbogast R, Martin L et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol. 1996;28:53-9.
80. Dixon RM, Cramer M, Shah AK et al. Single-dose, placebo-controlled, phase I study of oral dolasetron. Pharmacotherapy. 1996; 16:245-52.
81. Keung AC, Landriault H, Lefbvre M et al. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Biopharm Drug Dispos. 1997; 18:361-9.
82. Jantunen IT, Kataja W, Muhonen TT et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol. 1996; 37:502-4.
83. Watanabe H, Hasegawa A, Shinozaki T et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol. 1995; 35:278-82.
84. Carmichael J, Harris A. High-dose intravenous granisetron for the prevention of chemotherapy-induced emesis: cardiac safety and tolerability. Anticancer Drugs. 2003; 14:739-44.
85. Carmichael J, Harris A. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemother Pharmacol. 2004; 53:123-8.
86. Aapro M, Bourke J. Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: results of a pilot study. Eur J Cancer. 2003; 39:927-31.
87. Boike SC, Ilson B, Zariffa N et al. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health-Syst Pharm. 1997;54:1172-6.